Investigating the mechanisms of Modified Xiaoyaosan (tiaogan-liqi prescription) in suppressing the progression of atherosclerosis, by means of integrative pharmacology and experimental validation

Mingtai Chen; Yong Luo; Ling Men; Bo Lin; Haidan Lin; Ying Li; Guofu Zhong; Xiaoling Zhong; Wenjun Fu; Hua Zhou; Guangdong Tong; Qiang Liu; Jienan Luan

doi:doi:10.18632/aging.202832

← Back

Research Paper Volume 13, Issue 8 pp 11411—11432

Investigating the mechanisms of Modified Xiaoyaosan (tiaogan-liqi prescription) in suppressing the progression of atherosclerosis, by means of integrative pharmacology and experimental validation

Figure 3. GO and KEGG enrichment analysis of the key targets. (A) The top 20 significantly enriched terms in the GO biological processes; (B) The top 25 significantly enriched terms in KEGG pathways.